Stay updated with breaking news from Thyroid Eye Disease Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Data at Week 24 show 2.41 mm reduction in proptosis in patients treated with TEPEZZA compared with 0.92 mm in those who received placebo; 62% of TEPEZZA patients had clinically meaningful... | June 17, 2023
According to Horizon Therapeutics, the updated indication language reinforces the importance of access for patients across the full spectrum of TED activity or duration.
-- At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo -- -- 62% of patients treated with TEPEZZA had... | April 10, 2023
Announced today by Horizon Therapeutics, the positive and statistically significant data supports the efficacy of teprotumumab across a spectrum of patients with TED regardless of disease activity or duration.
Teprotumumab, a minimally invasive insulin-like growth factor I blocking antibody, has been shown to enhance symptoms, appearance, and quality of life in patients with thyroid eye disease, according to a study.